What is HC Wainwright’s Forecast for MNPR FY2026 Earnings?

Monopar Therapeutics Inc. (NASDAQ:MNPR) – HC Wainwright lifted their FY2026 EPS estimates for Monopar Therapeutics in a note issued to investors on Wednesday, January 22nd. HC Wainwright analyst S. Lee now anticipates that the company will post earnings per share of $0.70 for the year, up from their prior forecast of $0.12. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Monopar Therapeutics’ FY2027 earnings at $2.10 EPS and FY2028 earnings at $3.04 EPS.

A number of other research firms have also issued reports on MNPR. Rodman & Renshaw assumed coverage on shares of Monopar Therapeutics in a research note on Friday, October 11th. They set a “buy” rating and a $50.00 target price for the company. Piper Sandler initiated coverage on shares of Monopar Therapeutics in a research report on Friday, January 10th. They issued an “overweight” rating and a $72.00 price target on the stock.

Monopar Therapeutics Trading Up 16.8 %

Shares of Monopar Therapeutics stock opened at $39.32 on Friday. The stock has a market capitalization of $239.85 million, a price-to-earnings ratio of -19.96 and a beta of 1.23. Monopar Therapeutics has a twelve month low of $1.54 and a twelve month high of $39.99. The business’s 50 day simple moving average is $24.19 and its 200-day simple moving average is $12.34.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings results on Friday, November 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.09.

Insiders Place Their Bets

In other news, CFO Karthik Radhakrishnan purchased 1,550 shares of the business’s stock in a transaction dated Monday, October 28th. The stock was bought at an average cost of $16.25 per share, with a total value of $25,187.50. Following the purchase, the chief financial officer now directly owns 1,550 shares of the company’s stock, valued at approximately $25,187.50. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 34.90% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.